Nested Therapeutics CEO Darrin Miles (L) and CSO Klaus Hoeflich

Armed with $125M, Nest­ed Ther­a­peu­tics de­buts with plan to jump­start next-gen pre­ci­sion on­col­o­gy ef­forts

A new spin­out emerged from stealth Thurs­day morn­ing, backed by big name VCs and Big Phar­ma vet­er­ans at the helm to try to break in­to a new as­pect of pre­ci­sion on­col­o­gy med­i­cine.

The biotech, Nest­ed Ther­a­peu­tics, is run by two for­mer Genen­tech vet­er­ans who came to the start­up af­ter stints at Blue­print Med­i­cines and Agios, lead­ing a com­pa­ny that in­cludes for­mer Mer­ck drug hunter Yongx­in Han, who will head Nest­ed’s drug dis­cov­ery ef­forts. Oth­er Nest­ed co-founders in­clude Ke­van Shokat, the sci­en­tist whose team pub­lished the ground­break­ing pa­per in 2013 de­tail­ing how KRAS, once thought un­drug­gable, could be tar­get­ed. That pa­per ul­ti­mate­ly paved the way for Am­gen’s Lumakras, which got FDA ap­proval last year for lung can­cer with the mu­ta­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.